| AustriaAIHTA / SozialversicherungView country profile and sources → | Clinical assessment in the Austrian care setting; for hospital medicines, evidence to inform national funding decisions. | National PICO input is coordinated by care setting; AIHTA is developing Austria-specific fact sheets to contextualise JCA findings. | Use of JCA reports specified in national procedures |
| BelgiumRIZIV / INAMIView country profile and sources → | Therapeutic assessment within the national reimbursement process; a Belgian reimbursement application is still required. | Clinical data already submitted for the JCA need not be resubmitted; national PICO consultation is provided for. | Use of JCA reports specified in national procedures |
| BulgariaNCPRView country profile and sources → | Clinical and pharmacoeconomic HTA supporting national pricing and listing decisions. | National HTA rules explicitly provide for JCA; additional national information is required when a JCA report has been published. | Use of JCA reports specified in national procedures |
| CroatiaHZJZView country profile and sources → | Assessment of clinical effectiveness and safety alongside economic and other healthcare-system considerations. | A national legal framework has been published; clinicians and patients contribute to national PICO input. | Use of JCA reports specified in national procedures |
| CyprusGesundheitsministerium | The national criteria for medicines HTA have not been established in sufficient detail from the reviewed authority sources. | Participation in European HTA bodies is documented; national JCA dossier or assessment rules remain insufficiently evidenced. | National use of JCA reports not sufficiently documented |
| CzechiaSÚKLView country profile and sources → | National assessment for medicines reimbursement; detailed methodological requirements have not been fully verified here. | SÚKL has documented national PICO input and cooperation with patient organisations; subsequent use of JCA reports remains unclear. | Use of JCA reports specified in national procedures |
| DenmarkMedicinrådetView country profile and sources → | Clinical benefit versus comparators relevant to Danish practice, together with cost-effectiveness and budget impact. | The national dossier permits precise cross-references to JCA studies and analyses; additional local data and economic models remain necessary. | Use of JCA reports specified in national procedures |
| EstoniaRavimiamet / Tervisekassa | Clinical justification within the medicines reimbursement application; the detailed methodology has not been fully reviewed here. | No specific national adjustment for JCA could be established from the reviewed authority sources. | National use of JCA reports not sufficiently documented |
| FinlandFimeaView country profile and sources → | Therapeutic and economic value of hospital medicines in the Finnish care setting. | Where the PICO aligns, a national summary of the JCA may replace substantial clinical dossier content; economic assessment remains national. | Use of JCA reports specified in national procedures |
| FranceHAS / CTView country profile and sources → | The Transparency Committee assesses service médical rendu (SMR) and amélioration du service médical rendu (ASMR) for French reimbursement decisions. | HAS prepares national PICO input and has piloted patient-expert involvement; the SMR/ASMR assessment remains separate. | Use of JCA reports specified in national procedures |
| GermanyG-BA / IQWiGView country profile and sources → | AMNOG early benefit assessment: added benefit versus the appropriate comparator therapy (zVT), subject to specific statutory rules for orphan medicines. | The G-BA considered a JCA report in the completed tovorafenib assessment; the national added-benefit decision remains separate. | First national assessments using JCA reports completed |
| GreeceGesundheitsministerium | National medicines assessment and reimbursement; the specific assessment methods have not been fully verified here. | An official implementation project and legislative changes have been reported; binding JCA dossier implications have not been established from the reviewed sources. | National use of JCA reports not sufficiently documented |
| HungaryNEAKView country profile and sources → | Health economic assessment using nationally relevant costs, health outcomes and uncertainty assumptions. | National methodological guidance calls for a JCA aligned with the assessment scope when presenting relative efficacy and safety. | Use of JCA reports specified in national procedures |
| IcelandEEA · Lyfjastofnun | The national assessment criteria for medicines in the JCA context could not be established sufficiently from the reviewed sources. | A notice on HTA preparation was identified but not fully reviewed; national JCA rules and EEA legal status remain open. | National use of JCA reports not sufficiently documented |
| IrelandNCPEView country profile and sources → | National Rapid Review of clinical and economic considerations to inform a reimbursement recommendation. | NCPE used findings from the Itvisma JCA in a completed Rapid Review; this is not a final government reimbursement decision. | First national assessments using JCA reports completed |
| ItalyAIFA / CSEView country profile and sources → | Therapeutic need and added therapeutic value, alongside national pricing and reimbursement assessment. | Where a JCA is available, specified clinical study annexes (C.4–C.6) are optional under the applicable conditions; Italian comparators remain relevant. | Use of JCA reports specified in national procedures |
| LatviaZVA | The national medicines assessment criteria and reimbursement responsibilities are not sufficiently clarified by the reviewed sources. | ZVA participation in European HTA bodies is documented, but national JCA dossier rules are not. | National use of JCA reports not sufficiently documented |
| LiechtensteinEEA · Amt für Gesundheit | A distinct national medicines HTA framework for the JCA context has not been established from the sources. | No specific national JCA integration has been evidenced; applicability through the EEA requires separate verification. | National use of JCA reports not sufficiently documented |
| LithuaniaVVKTView country profile and sources → | National health technology assessment; the specific criteria for medicines reimbursement are not sufficiently evidenced here. | VVKT provided national PICO input for the 13 JCAs started in 2025; subsequent national use of the reports remains unclear. | Use of JCA reports specified in national procedures |
| LuxembourgDirection de la santé / DPM | The national medicines assessment framework is not described in sufficient detail by the reviewed sources. | An HTAR implementation review was documented in 2022; this does not establish current national JCA procedures. | National use of JCA reports not sufficiently documented |
| MaltaHTA Unit | Clinical evidence supporting decisions on inclusion in the Government Formulary. | The reviewed authority sources do not establish specific JCA-related changes to the listing process. | National use of JCA reports not sufficiently documented |
| NetherlandsZorginstituut NederlandView country profile and sources → | Assessment for the statutory basic benefits package, covering clinical, pharmacoeconomic and budget-impact considerations. | National PICO consultation and use of JCA reports in the Dutch assessment process are described; the benefits-package decision remains national. | Use of JCA reports specified in national procedures |
| NorwayEEA · DMPView country profile and sources → | National metodevurdering to inform public funding of medicines, including health economic assessment. | DMP has adapted dossier templates for JCA and offers early discussion of Norwegian PICO requirements and supplementary documentation. | Use of JCA reports specified in national procedures |
| PolandAOTMiTView country profile and sources → | National medicines reimbursement assessment; detailed clinical assessment criteria have not been fully verified here. | National law provides for consideration of JCA within the reimbursement framework; specific submission implications remain to be clarified. | Use of JCA reports specified in national procedures |
| PortugalINFARMED / CATS | Added therapeutic value (VTA) or therapeutic equivalence, together with economic advantage under SiNATS. | Available INFARMED documents set out national assessment criteria but do not establish a specific JCA-related procedural change. | National use of JCA reports not sufficiently documented |
| RomaniaANMDMR | National medicines HTA; specific criteria have not been sufficiently verified in the reviewed sources. | Participation in the European HTA Coordination Group is documented, but national JCA procedural rules are not. | National use of JCA reports not sufficiently documented |
| SlovakiaNIHO | National medicines assessment against statutory criteria; the detailed methodology has not been fully reviewed here. | NIHO confirms participation in European JCAs; the reviewed sources do not establish national dossier adjustments. | National use of JCA reports not sufficiently documented |
| SloveniaGesundheitsministerium | An HTA system for medical devices and in-vitro diagnostics is being developed; medicines HTA criteria are not sufficiently evidenced here. | The identified implementation work concerns devices and IVDs; no specific rules for using medicinal-product JCAs have been established. | National use of JCA reports not sufficiently documented |
| SpainAEMPS / Ministerio de SanidadView country profile and sources → | National clinical and wider HTA assessment to support pricing, funding and reimbursement decisions. | The 2026 HTA framework provides for JCA integration; additional dossier and procedural rules were still under consultation in November. | Use of JCA reports specified in national procedures |
| SwedenTLV / SBUView country profile and sources → | Relative clinical effect and cost-effectiveness in Swedish care, particularly for pricing and subsidy decisions. | TLV and SBU have specified PICO coordination and use of JCA findings; initial national assessments involving JCA have started. | Use of JCA reports specified in national procedures |